Cerba Research and Ozette Technologies Announce Partnership to Advance High‑Dimensional Immune Profiling and Improve Clinical Decision-Making
Combining integrated spectral flow cytometry and cloud‑native AI-enabled analytics to deliver scalable, standardized immune insights that de-risk drug development and accelerate translational and clinical research.
Paris, France and Seattle, WA – April 16, 2026 – Cerba Research, a global leader in specialty laboratory services and translational research, today announced a strategic partnership with Ozette Technologies, Inc. (Ozette), an innovator in high‑dimensional spectral flow cytometry and AI-driven single‑cell data analytics.
This collaboration addresses a critical challenge in drug development: translating complex immune data into clear, actionable insights that can guide faster, more confident exploratory clinical decisions for patients.
The partnership brings together Cerba Research’s global laboratory network and scientific expertise with Ozette’s proprietary 48-color spectral flow pan‑immune profiling assay (PIP 01) and cloud‑native data analytics platform to deliver standardized, scalable immune profiling workflows across translational research and clinical development programs.
Together, Cerba Research and Ozette aim to accelerate immune‑centric discovery, biomarker development, mechanism‑of‑action studies, and immune monitoring by connecting high‑quality data generation with advanced, reproducible analytics, from data acquisition through actionable insight that help de-risk drug development.
“Immune profiling is foundational to modern drug development yet increasing assay complexity and analytical variability often limit interpretability,” said Maria Fotiu, CEO, Cerba Research. “By partnering with Ozette, we are combining scientific rigor at the laboratory bench with computational precision in the cloud. This collaboration strengthens our ability to deliver standardized, high‑dimensional immune insights that our biopharma partners can trust – across studies, sites, and clinical programs. Ultimately, this means our partners can make more confident decisions that directly impact how quickly, and effectively new therapies reach patients.”
Advancing Immune Insight: From Acquisition to Analysis
Under the agreement, Cerba Research will perform and further customize Ozette’s PIP 01 spectral flow cytometry assay within its laboratories to support a wide range of research and clinical applications. All data generated from PIP 01 and derivative immune panels will be analyzed using the Ozette Platform, a secure, cloud‑native data analysis solution providing Ozette’s adaptive spectral unmixing, data quality control, AI and ML-powered data analysis, collaboration tools, and standardized reporting.
Cerba Research will also apply the Ozette Platform to data generated from its internally developed spectral flow cytometry panels, enabling a unified analytical framework across programs. The result is an end‑to‑end, standardized immune profiling workflow that reduces variability, improves reproducibility, and enables deeper biological interpretation at scale.
“Spectral flow cytometry delivers extraordinary biological resolution, but only when paired with the right tools, safeguards and analytical framework that can detect, correct, and prevent data quality problems throughout the workflow. This allows more robust decision-making downstream based on high quality, reliable and trustworthy insights.” said Greg Finak, CEO and Co-founder, Ozette. “Cerba Research is a trusted global laboratory partner, and together we are setting a new benchmark for data quality and how high‑dimensional immune profiling data are generated, analyzed, and delivered for translational and clinical impact.”
Designed to Support Diverse Immune-Driven Programs
The collaboration supports immune profiling strategies across a broad range of therapeutic applications, including:
- Autoimmune and inflammatory disease research requiring deep immune phenotyping
- Infectious disease programs focused on immune response characterization and durability
- Rare disease studies where immune signatures inform patient stratification
- Translational programs exploring immune involvement outside traditional immuno-oncology settings
This flexible approach allows sponsors to apply consistent immune analytics while adapting assay design and interpretation to the biology of each disease area.
The Ozette platform incorporates advanced computational methods, including AI‑ and machine‑learning-driven analytics, to support rapid quality assessment, standardized endpoint analysis, and clear, actionable reporting within a centralized, secure environment. All assays and analytical services provided under this collaboration are designated for research use only (RUO).*
A Shared Commitment to Scientific Transparency
Cerba Research and Ozette share a commitment to scientific transparency, data ownership, and analytical rigor. Cerba Research retains ownership of generated results, while the Ozette platform ensures de‑identified data handling and robust security standards aligned with global research requirements. This partnership reflects a shared philosophy: advanced technology should not obscure biology but clarify it.
By combining advanced laboratory science with scalable analytics, Cerba Research and Ozette are helping transform complex immune data into decisions that matter, bringing greater precision, speed, and confidence to the development of therapies for patients worldwide.
*Regulatory Disclaimer
The assays, software, analytical platforms, and services described herein are intended for research use only (RUO). They have not been reviewed or approved by the U.S. Food and Drug Administration (FDA), do not constitute medical devices or in vitro diagnostic medical devices under applicable U.S. or EU regulations (including MDR and IVDR), and are not intended for diagnostic use or to support clinical decision-making or patient care.
About Cerba Research
Cerba Research is a global specialty laboratory and research services organization supporting biopharmaceutical development from discovery through clinical trials. As part of Cerba HealthCare, a leading global player in medical diagnostics with nearly 60 years of expertise in medical biology, Cerba Research delivers high quality data, scientific insight, and operational excellence across immunology, oncology, infectious diseases, and rare diseases to partners worldwide.
For more information, please visit https://www.cerbaresearch.com/
About Ozette
Ozette is a biotechnology company pioneering vertically integrated, computationally driven solutions for deep immune profiling. By combining advanced AI and ML powered analytics with high-quality, high-dimensional single-cell spectral flow cytometry data, Ozette translates complex immunological signals into actionable insights. This enables biopharmaceutical partners to de-risk development and accelerate precision therapies for complex diseases.
For more information, please visit: https://www.ozette.com/
